

| Dosage | Package | Price per Dose | Price | |
|---|---|---|---|---|
| 60mg | 240 pills | €1.19 | €381.03 €285.77 Best Price | |
| 60mg | 180 pills | €1.24 | €296.78 €222.58 | |
| 60mg | 120 pills | €1.34 | €214.44 €160.83 | |
| 60mg | 90 pills | €1.41 | €168.48 €126.36 | |
| 60mg | 60 pills | €1.51 | €120.61 €90.46 | |
| 60mg | 30 pills | €1.71 | €68.91 €51.69 | |
| 90mg | 240 pills | €1.85 | €593.57 €445.18 | |
| 90mg | 180 pills | €1.88 | €451.88 €338.91 | |
| 90mg | 120 pills | €1.92 | €308.27 €231.20 | |
| 90mg | 90 pills | €2.01 | €241.25 €180.94 | |
| 90mg | 60 pills | €2.11 | €168.48 €126.36 | |
| 90mg | 30 pills | €2.27 | €89.98 €67.48 | |
| 120mg | 240 pills | €2.15 | €689.31 €516.99 Popular | |
| 120mg | 180 pills | €2.20 | €526.55 €394.92 | |
| 120mg | 120 pills | €2.24 | €358.05 €268.54 | |
| 120mg | 90 pills | €2.36 | €283.37 €212.53 | |
| 120mg | 60 pills | €2.47 | €197.21 €147.91 | |
| 120mg | 30 pills | €2.64 | €105.30 €78.97 |
Disclaimer: This leaflet provides general information about Arcoxia. It is not a substitute for professional medical advice from a pharmacist or doctor.
Arcoxia is a brand name for the medicine whose active ingredient is etoricoxib. Etoricoxib belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs) with a specific focus on the COX-2 enzyme (cyclooxygenase‑2) in the body. This selective action reduces inflammation and pain while aiming to lower certain side effects associated with older NSAIDs that block both COX‑1 and COX‑2 enzymes.
The active ingredient, etoricoxib, is formulated to be taken by adults under medical supervision. The product is prescribed to relieve pain and swelling in musculoskeletal conditions where inflammation is present. The medication is supplied by a pharmacist and is used as directed by a clinician or pharmacist in the context of a patient’s overall treatment plan.
In Ireland, Arcoxia usage is subject to local medical rules and prescription status. Availability and eligibility may depend on national guidelines and individual clinical assessment. Compliance with the official patient information leaflet and professional guidance is essential for safe use.
Safety information is provided here to support informed use. If questions arise, consult a pharmacist or doctor for personalised advice, including confirmation of the most appropriate dose and duration for a given condition.
Arcoxia is intended to relieve pain and reduce inflammation in several inflammatory or degenerative musculoskeletal conditions. The exact benefit is determined by the condition, the severity of symptoms, and the response to ongoing treatment.
Commonly encountered situations where Arcoxia may be prescribed include joint-related pain and stiffness, especially when inflammation is a contributing factor. It is not a cure for underlying disease; rather, it helps manage symptoms to improve function and comfort during daily activities.
In practice, the treating clinician determines suitability based on individual health status, risk factors, and concurrent medications. If symptoms persist or worsen, or if there is any uncertainty about the appropriateness of Arcoxia, a healthcare professional should be consulted promptly.
Arcoxia is not intended for routine, long-term relief without clinical oversight. Treatment decisions should reflect a balance between expected benefit and potential risks, as explained in the official leaflets and by a pharmacist.
Arcoxia selectively inhibits the COX-2 enzyme. This enzyme normally converts arachidonic acid into prostaglandins, chemical mediators that contribute to pain, swelling, and heat in inflamed tissues. By reducing prostaglandin production in affected areas, discomfort and inflammation can lessen.
The COX-2 selective action aims to preserve some protective functions of COX‑1 in the stomach and kidneys, potentially altering the risk profile compared with non‑selective NSAIDs. Nonetheless, all NSAIDs carry potential risks for the stomach, heart, and kidneys, and careful assessment is advised before starting therapy.
In practical terms, Arcoxia is used to ease pain related to inflammatory processes and to improve joint mobility and daily function when inflammation is present. The response to treatment is individualized and may vary between patients and conditions.
Overall, the intended effect is symptom relief and improved ability to participate in daily activities, with attention to monitoring for any adverse effects or interactions as guided by a healthcare professional.
Dosage and duration are determined by the prescriber based on the diagnosed condition, patient age, kidney and liver function, and response to treatment. Only the clinician or pharmacist can decide the appropriate dose for an individual patient. The instructions on the product label and the patient information leaflet should be followed precisely.
The usual directions include swallowing the tablet whole with a glass of water. Arcoxia may be taken with or without food, but taking it with food can help lessen stomach-related upset in some individuals. The timing of daily intake should be consistent to maintain a steady level of the medicine in the body.
Before taking Arcoxia, it is important to consider certain factors and report them to the prescriber. See the listed precautions and potential interactions, and consult a healthcare professional for personalised guidance prior to initiation or changes in therapy.
When starting treatment or adjusting the dose, the clinician may monitor symptoms, side effects, and laboratory parameters (such as kidney function) to ensure safe and effective use. If there is any doubt about how to take the medicine, ask the pharmacist for clarification or a patient information leaflet for review.
Contraindications describe situations where Arcoxia should not be used because the potential for harm outweighs any expected benefit. The decision to avoid Arcoxia relies on a clinician’s assessment of risks versus benefits for the individual patient.
Known conditions or circumstances that commonly prevent use include a history of hypersensitivity to etoricoxib or other NSAIDs, active ulcer or bleeding in the stomach or intestines, and significant kidney or liver impairment. Other contraindications may include severe heart failure or certain cardiovascular conditions where NSAID use requires careful consideration.
Pregnancy status and lactation are also considered carefully, with guidance from a clinician about whether alternative treatments are safer. In case of any previous adverse reaction to NSAIDs, caution is advised and professional advice should be sought before starting Arcoxia.
If any of these conditions apply, or if there is uncertainty about suitability, a clinician or pharmacist should be consulted before initiating Arcoxia. The patient information leaflet supplied with the medication provides additional detail and should be reviewed.
Several warnings and precautions accompany Arcoxia therapy. The aim is to minimise risks while providing symptom relief. A clinician will determine whether these precautions apply in a given case based on medical history and current medicines.
Cardiovascular safety is an important consideration. NSAIDs, including COX‑2 inhibitors, may increase the risk of cardiovascular events such as heart attack or stroke, particularly with long-term use or in patients with existing cardiovascular risk factors. The lowest effective dose for the shortest period should be used, and ongoing assessment is advised.
Gastrointestinal safety is also important. Although COX‑2 selectivity reduces some GI risks, gastrointestinal ulcers, bleeding, or perforation can still occur, including without warning signs. Patients with a history of GI problems should be monitored closely.
Renal function may be affected. Arcoxia can influence kidney function, especially in dehydration, heart failure, or pre‑existing kidney disease. Adequate hydration and monitoring of kidney parameters are advised during treatment.
Other cautions include checking for liver disease, high blood pressure, and fluid retention. If any new symptoms develop, such as persistent abdominal pain, vomiting blood, severe stomach cramps, yellowing of skin or eyes, swelling of limbs, shortness of breath, or chest pain, seek urgent medical help or contact a healthcare professional promptly.
Side effects may occur with any medicine and vary between individuals. Common effects are typically mild and transient, but some can be more serious. The likelihood and severity of side effects depend on factors such as dose, duration of therapy, and individual risk factors.
Most people experience no or mild adverse effects. When they occur, common events often involve the gastrointestinal system or central nervous system, such as indigestion, stomach discomfort, nausea, diarrhoea, headache, or dizziness. These usually improve with short-term use or after dose adjustments under professional guidance.
Serious adverse effects require prompt medical attention. These may include signs of stomach or intestinal bleeding (such as black, tarry stools or vomiting blood), severe allergic reactions, liver injury (yellowing of the skin or eyes, dark urine), kidney problems (changes in urine output), severe skin reactions, or chest pain. In the event of any concerning symptoms, consult a clinician or pharmacist promptly and seek urgent medical help if needed.
Patients should contact a healthcare professional if persistent or worsening side effects occur, or if they have questions about managing symptoms while taking Arcoxia. The official leaflet contains a full list of possible adverse effects and instructions on how to respond if they occur.
Arcoxia can interact with other medicines, foods, or supplements, altering effectiveness or increasing the risk of adverse effects. The prescriber will review current therapies to minimise potential interactions.
Interactions of particular importance include concurrent use with other NSAIDs, aspirin at higher doses, anticoagulants, and certain antidepressants or medicines that affect kidney function. Some blood pressure medications may interact, affecting blood pressure control. Alcohol should be discussed with a clinician, as it can exacerbate stomach irritation in some individuals.
It is essential to inform the pharmacist about all medicines, supplements, and herbal products being taken. Do not start or stop medicines without professional guidance. If new medicines are prescribed, a clinician should assess for potential interactions with Arcoxia.
Grapefruit juice and certain foods are not universally contraindicated with Arcoxia, but it is prudent to discuss dietary considerations with a pharmacist, especially if taking multiple medicines. If uncertain, check the official leaflet or consult a healthcare professional.
Pregnancy requires careful consideration of the risks and benefits of all medicines. Arcoxia is generally advised against during pregnancy, particularly in the later stages, unless explicitly directed by a clinician who has assessed the individual case. If pregnancy is planned or suspected, medical advice should be sought promptly.
Breastfeeding while taking Arcoxia should be discussed with a clinician. It is not clear how etoricoxib may affect a nursing infant, and a pharmacist or doctor can provide guidance on safe alternatives if required.
In all cases, the decision to use Arcoxia during pregnancy or breastfeeding rests on clinical judgement, along with a patient’s health status and treatment goals. If there is any possibility of pregnancy during treatment, consult a healthcare professional for personalized advice before continuing therapy.
When assessing use in pregnancy and lactation, reference to the official patient information leaflet and professional guidance is recommended to ensure safety for both mother and child.
Allergic reactions may occur with NSAIDs, including those that selectively inhibit COX‑2. A clinician should be informed of any prior reactions to NSAIDs, including symptoms such as hives, swelling, or trouble breathing. If a reaction is suspected after taking Arcoxia, medical advice should be sought promptly.
In the event of a missed dose, seek guidance from a clinician or pharmacist. Do not double the next dose unless advised. A healthcare professional can provide instructions tailored to the prescribed regimen and the timing of the missed dose.
Moderation is advised and the risk of stomach irritation may be increased with alcohol. The clinician will consider the overall treatment plan and advise on possible interactions or adjustments if alcohol consumption is anticipated during therapy.
The duration of treatment is determined by a clinician based on the condition being treated and response to therapy. Regular review is recommended to assess ongoing benefit and potential risks. Do not continue a course longer than advised without professional input.
Arcoxia may be used for certain acute pain settings as directed by a clinician. The appropriateness depends on individual health status and concurrent medications. A dentist or clinician will advise on suitability for dental‑related pain in each case.
The presence of high blood pressure requires careful assessment, as NSAIDs can influence blood pressure and fluid balance in some individuals. A clinician will evaluate cardiovascular risk and decide on the safest option for pain management.
NSAIDs can affect kidney and liver function in some people. Baseline assessment and periodic monitoring may be advised, especially in those with pre‑existing kidney or liver conditions, older adults, or those using other medicines affecting organ function. Report unusual symptoms such as decreased urine output, swelling, or yellowing of the skin or eyes promptly.
Long‑term use may carry increasing risks, including cardiovascular, gastrointestinal, and renal effects. The decision for extended therapy is made by a clinician who weighs potential long‑term benefits against risks and who conducts appropriate monitoring during treatment.
Yes. The leaflet provides detailed information on indications, contraindications, dosing, possible side effects, and precautions. It should be read in conjunction with professional advice. Check with a pharmacist or doctor if any point is unclear.
If there is insufficient relief or if symptoms worsen, contact a healthcare professional. A reassessment may be required to adjust the treatment plan or consider alternative therapies. Do not continue a treatment that is not providing benefit without professional guidance.
Official patient information leaflets accompany Arcoxia and provide detailed guidance on use, safety, and storage. These leaflets are prepared to support safe, effective use and should be consulted alongside advice from a pharmacist or clinician.
Healthcare professionals, including pharmacists, can answer questions about how Arcoxia relates to existing medical conditions, current medications, and individual risk factors. A clinician can tailor advice to the patient’s health history and treatment goals.
For further information, refer to the official documentation supplied with the product and contact a local pharmacy for personalised guidance. When in doubt, seek professional advice before initiating or continuing therapy with Arcoxia.
In Ireland, it is important to follow national guidelines and the prescribing clinician’s directions. The information provided here is intended to support safe use in conjunction with professional medical care and the official product leaflet. Seek urgent medical help if severe symptoms or signs of a serious adverse reaction occur.
14–21 days. Free from €173.03 .
5–9 days. €25.95
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
